Patients with chronic phase chronic myeloid leukemia (CML) and pre-existing mild to moderate liver and/or renal dysfunction can be safely treated with frontline nilotinib or dasatinib, according to a new study by Cortez et al from MD Anderson Cancer Center, USA.
?The 69% of those with normal organ function who achieved molecular response of 4.5 log reduction of bcr-c.abl messenger RNA (an MR4.5 response) is almost identical to the 64% MR4.5 response seen in patients with liver dysfunction (P = .617) and 60% of those renal dysfunction (P = .565).? These results were published in the March issue of Clinical Lymphoma, Myeloma, & Leukemia.
CML is the commonest blood cancer in India. It is regularly treated at Asian Cancer Institute ?- including with both these drugs (nilotinib and dasatinib). We also assist in procuring these medicines from the manufacturer to reduce cost.